Mangoceuticals, Inc. (MGRX)

Mangoceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Net Income	-14.2	-8.71	-9.21	-2
Depreciation & Amortization	0	0.73	0.02	0
Stock-Based Compensation	6.26	2.35	2.16	0.77
Other Adjustments	0.09	0.1	0.05	-0.32
Changes in Inventories	-	-	-0.02	-
Changes in Accounts Payable	0.58	0.7	0.11	0.03
Changes in Other Operating Activities	-0.31	-0.04	-0.1	0.16
Operating Cash Flow	-5.83	-4.86	-7	-1.35
Capital Expenditures	-	-	-0	-0.04
Sale of Property, Plant & Equipment	-	0.07	-	-
Investing Cash Flow	-	0.07	-0	-0.04
Long-Term Debt Issued	-	0.15	-0.08	0.08
Long-Term Debt Repaid	-	-	-0.09	-0.03
Net Long-Term Debt Issued (Repaid)	-	0.15	-0.17	0.05
Issuance of Common Stock	-	1.33	7.22	2
Net Common Stock Issued (Repurchased)	-	1.33	7.22	2
Issuance of Preferred Stock	1.25	2.65	-	-
Net Preferred Stock Issued (Repurchased)	1.25	2.65	-	-
Financing Cash Flow	5.44	4.13	7.06	2.05
Effect of Exchange Rate Changes on Cash and Cash Equivalents	-0	-0.01	-	-
Net Cash Flow	-0.39	-0.67	0.06	0.66
Beginning Cash & Cash Equivalents	0.49	0.74	0.68	0.02
Ending Cash & Cash Equivalents	0.1	0.06	0.74	0.68
Free Cash Flow	-5.83	-4.86	-7	-1.39
FCF Margin	-1129.13%	-789.74%	-957.07%	-15545.59%
Free Cash Flow Per Share	-1.22	-2.46	-6.52	-1.93
Levered Free Cash Flow	-13.93	-7.16	-9.37	-1.79
Unlevered Free Cash Flow	-13.29	-6.58	-9.21	-1.84

Updated Jun 30, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q